Literature DB >> 7737650

Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts.

H Yokoyama1, S Nagata, S Moriya, S Kato, T Ito, K Kamegaya, H Ishii.   

Abstract

Experimental hepatic fibrosis was produced in the guinea pig. We produced hepatic necrosis associated with inflammatory cell infiltration in guinea pigs immunized with acetaldehyde adducts and fed ethanol for 40 days. Extending the period of these treatments to 90 days resulted in producing hepatic fibrosis developing around individual hepatocytes in the terminal hepatic venule areas and portal areas, accompanied by an increase in hepatic hydroxyproline content. In contrast, no fibrosis was observed in the livers of the control groups that had been exposed to nothing, ethanol alone, or a combination of ethanol and immunization with unmodified human hemoglobin. Minimal fibrotic changes were observed in animals immunized with human hemoglobin acetaldehyde adducts but not fed ethanol. These results indicate that the formation of acetaldehyde adducts and the acquisition of immunity against them can produce hepatic fibrosis. Immune mechanisms against acetaldehyde adducts may, in part, be involved in the pathogenesis of hepatic fibrosis seen in alcoholics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737650

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Coagulation protein function VII: diametric effects of acetaldehyde on factor VII and factor IX function.

Authors:  D A Sabol; M H Basista; A S Brecher; K Haider; J Kleshinski
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-06-15       Impact factor: 3.199

3.  Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease.

Authors:  Wei-Xing Chen; You-Ming Li; Chao-Hui Yu; Wei-Min Cai; Min Zheng; Feng Chen
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

4.  Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy").

Authors:  Vijay V Upreti; Natalie D Eddington; Kwan-Hoon Moon; Byoung-Joon Song; Insong J Lee
Journal:  Toxicol Lett       Date:  2009-04-05       Impact factor: 4.372

Review 5.  "Second hit" models of alcoholic liver disease.

Authors:  Hidekazu Tsukamoto; Keigo Machida; Alla Dynnyk; Hasmik Mkrtchyan
Journal:  Semin Liver Dis       Date:  2009-04-22       Impact factor: 6.115

6.  Additive effect of alpha-tocopherol and ascorbic acid in combating ethanol-induced hepatic fibrosis.

Authors:  P Prathibha; S Rejitha; R Harikrishnan; S Syam Das; P A Abhilash; M Indira
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

Review 7.  Acetaldehyde adducts in alcoholic liver disease.

Authors:  Mashiko Setshedi; Jack R Wands; Suzanne M de la Monte
Journal:  Oxid Med Cell Longev       Date:  2010 May-Jun       Impact factor: 6.543

8.  Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center.

Authors:  Xu Li; Hongqin Xu; Pujun Gao
Journal:  Med Sci Monit       Date:  2020-11-12

9.  Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection.

Authors:  Sha Lin; QinQin Sun; WeiLin Mao; Yu Chen
Journal:  Gastroenterol Res Pract       Date:  2016-03-30       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.